Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

GB Appel; G Contreras; MA Dooley; EM Ginzler; D Isenberg; D Jayne; LS Li; E Mysler; J Sánchez-Guerrero; N Solomons; D Wofsy; C Abud; S Adler; G Alarcón; E Albuquerque; F Almeida; A Alvarellos; H Avila; C Blume; I Boletis; A Bonnardeaux; A Braun; J Buyon; R Cervera; N Chen; S Chen; AG Da Costa; R Davids; D D'Cruz; E De Ramón; A Deodhar; A Doria; B Dussol; P Emery; J Fiechtner; J Floege; H Fragoso-Loyo; R Furie; R Ghazalli; C Ghossein; G Gilkeson; E Ginzler; C Gordon; J Grossman; J Gu; L Guillevin; PY Hatron; G Herrera; F Hiepe; F Houssiau; O Hübscher; C Hura; J Kaplan; G Kirsztajn; E Kiss; GA Kutty; M Laville; M Lazaro; O Lenz; L Lightstone; S Lim; M Malaise; S Manzi; J Marcos; O Meyer; P Monge; S Naicker; N Neal; M Neuwelt; K Nicholls; N Olsen; J Ordi-Ros; B Ostrov; M Pestana; M Petri; G Pokorny; J Pourrat; J Qian; J Radhakrishnan; B Rovin; JS Roman; J Shanahan; W Shergy; F Skopouli; A Spindler; C Striebich; R Sundel; C Swanepoel; YT Si; G Tate; V Tesaŕ; M Tikly; H Wang; R Yahya; X Yu; F Zhang; D Zoruba

Journal article

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

GB Appel, G Contreras, MA Dooley, EM Ginzler, D Isenberg, D Jayne, LS Li, E Mysler, J Sánchez-Guerrero, N Solomons, D Wofsy, C Abud, S Adler, G Alarcón, E Albuquerque, F Almeida, A Alvarellos, H Avila, C Blume, I Boletis Show all

Journal of the American Society of Nephrology | AMER SOC NEPHROLOGY | Published : 2009

DOI: 10.1681/ASN.2008101028

Abstract

Recent studies have suggested that mycophenolate mofetil (MMF) may offer advantages over intravenous cyclophosphamide (IVC) for the treatment of lupus nephritis, but these therapies have not been compared in an international randomized, controlled trial. Here, we report the comparison of MMF and IVC as induction treatment for active lupus nephritis in a multinational, two-phase (induction and maintenance) study. We randomly assigned 370 patients with classes III through V lupus nephritis to open-label MMF (target dosage 3 g/d) or IVC (0.5 to 1.0 g/m2 in monthly pulses) in a 24-wk induction study. Both groups received prednisone, tapered from a maximum starting dosage of 60 mg/d. The primary ..

View full abstract